{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-045723","form_type":"8-K","ticker":"EQ","cik":"0001746466","company_name":"Equillium, Inc.","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.697528+00:00","generated_at":"2026-05-24T04:00:00.650659+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Equillium Reports Q4 and Full Year 2024 Financial Results and Provides Clinical Updates","bullets":["Phase 3 EQUATOR study in aGVHD: primary endpoint not met, but statistically significant longer-term outcomes (CR at Day 99, duration of CR, failure-free survival).","Full year 2024 revenue $41.1M, up from $36.1M in 2023; net loss $8.1M ($0.23/share) vs $13.3M ($0.38/share) in 2023.","Cash and investments $22.6M as of Dec 31, 2024; expected to fund operations into Q3 2025.","FDA meeting requested for Accelerated Approval of itolizumab in aGVHD; feedback expected May 2025.","Positive Phase 2 data for itolizumab in ulcerative colitis: clinical remission rate 23.3% vs 10.0% placebo at 12 weeks."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-045723","json":"https://secwatch.observer/filing/0000950170-25-045723.json","markdown":"https://secwatch.observer/filing/0000950170-25-045723.md","text":"https://secwatch.observer/filing/0000950170-25-045723.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746466/000095017025045723/0000950170-25-045723-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746466/000095017025045723/eq-20250327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-24T04:00:00.650659+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}